Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical
company focused on advancing innovative treatments for spinal
muscular atrophy (SMA), cardiometabolic disorders, and other
serious diseases where protein growth factors play a fundamental
role, today announced the appointment of Katie Peng to Scholar
Rock’s Board of Directors and the promotion of Mo Qatanani, Ph.D.,
to Chief Scientific Officer.
“We are pleased to welcome Katie to Scholar Rock’s Board of
Directors at a pivotal time when the company is preparing for the
potential launch of apitegromab next year,” said David Hallal,
Chairman of the Board of Scholar Rock. “Katie brings deep
commercial expertise in neurology and rare diseases and has a
strong understanding of SMA from her experience launching Evrysdi
while she was a business unit head at Genentech. Katie joining our
Board reflects the continued evolution of Scholar Rock, and as part
of this process, Amir Nashat will be stepping down from the Board
at this year’s annual shareholder meeting. Amir has made
significant contributions to the growth of Scholar Rock since
joining the board in 2012, and we extend our sincere gratitude to
him for his unwavering dedication to the company.”
Ms. Peng is an accomplished biotechnology executive with over
three decades of deep commercial experience in neurology and rare
diseases, and she is currently the Chief Commercial Officer at
Denali Therapeutics. Prior to joining Denali, Ms. Peng managed a
neurology, ophthalmology, immunology, and rare disease portfolio
representing approximately $14 billion in revenue at Genentech. She
has successfully launched multiple products in neurology, oncology,
and rare disease, notably Evrysdi® (risdiplam) at Genentech, a
medicine used to treat spinal muscular atrophy (SMA) in adults and
children. Before that, Ms. Peng was at Roche Holding AG, where she
was the General Manager of both Taiwan and Singapore, managing the
portfolio of over 30 products in the Asia Pacific region. Earlier
in her career, she held multiple commercial roles at Amgen Inc. and
was a research scientist at Allergan plc. Ms. Peng holds an MBA
from the Kelley School of Business, Indiana University and a B.A.
from the University of California, Berkeley. She also serves as a
board member for California Life Sciences and Adicet Bio.
“I am thrilled to join Scholar Rock’s Board of Directors as the
company prepares for its first potential commercial launch of
apitegromab. I look forward to working with the team and sharing my
experience and expertise to successfully bring apitegromab to
people living with SMA,” said Ms. Peng.
“In addition to having Katie join our Board, I am excited by the
continued progress of our preclinical programs, including
additional work in developing SRK-439 for cardiometabolic
disorders. Mo has been a driving force in advancing our early-stage
pipeline, especially the cardiometabolic program, and it is my
pleasure to announce his promotion to Chief Scientific Officer. He
has been an outstanding leader of our research organization and a
key member of the leadership team,” said Jay Backstrom, M.D., MPH,
President and Chief Executive Officer of Scholar Rock.
Dr. Qatanani joined Scholar Rock in 2021 and, since 2022, has
been leading all research functions, including discovery biology,
protein sciences & antibody engineering, nonclinical safety,
and translational sciences. He brings over 15 years of discovery
and translational research experience in developing and advancing
multiple therapeutic modalities in the neuromuscular and
cardiometabolic disease areas.
Prior to Scholar Rock, Dr. Qatanani was a founding employee,
vice president, and Head of Research at Dyne Therapeutics, where he
built the research organization from the ground up to launch and
advance to the clinic multiple therapeutic programs for rare
neuromuscular diseases. Before that, he held research positions of
increasing responsibility at Alexion Pharmaceuticals, Synageva
BioPharma, and Merck. Dr. Qatanani holds a Ph.D. in Molecular and
Human Genetics from Baylor College of Medicine and completed a
post-doctoral fellowship at the Institute for Diabetes, Obesity and
Metabolism at the University of Pennsylvania School of Medicine. He
has a B.Sc. and a M.Sc. in Biology from the American University of
Beirut.
“Scholar Rock is known for its pioneering scientific research,
particularly in the unparalleled selective targeting of the latent
forms of growth factors, and I am proud to be able to lead these
efforts during this exciting stage of the company’s growth, and to
help translate this groundbreaking science into transformative
therapies that have the potential to improve peoples’ lives,” said
Dr. Qatanani.
About Scholar Rock
Scholar Rock is a biopharmaceutical company that discovers,
develops, and delivers life-changing therapies for people with
serious diseases that have high unmet need. As a global leader in
the biology of the transforming growth factor beta (TGFβ)
superfamily of cell proteins and named for the visual resemblance
of a scholar rock to protein structures, the clinical-stage company
is focused on advancing innovative treatments where protein growth
factors are fundamental. Over the past decade, Scholar Rock has
created a pipeline with the potential to advance the standard of
care for neuromuscular disease, cardiometabolic disorders, cancer,
and other conditions where growth factor-targeted drugs can play a
transformational role.
Scholar Rock is the only company to show clinical proof of
concept for a muscle-targeted treatment in spinal muscular atrophy
(SMA). This commitment to unlocking fundamentally different
therapeutic approaches is powered by broad application of a
proprietary platform, which has developed novel monoclonal
antibodies to modulate protein growth factors with extraordinary
selectivity. By harnessing cutting-edge science in disease spaces
that are historically under-addressed through traditional
therapies, Scholar Rock works every day to create new possibilities
for patients. Learn more about our approach at ScholarRock.com and
follow @ScholarRock and on LinkedIn.
Availability of Other Information About Scholar Rock
Investors and others should note that we communicate with our
investors and the public using our company website
www.scholarrock.com, including, but not limited to, company
disclosures, investor presentations and FAQs, Securities and
Exchange Commission filings, press releases, public conference call
transcripts and webcast transcripts, as well as on Twitter and
LinkedIn. The information that we post on our website or on Twitter
or LinkedIn could be deemed to be material information. As a
result, we encourage investors, the media and others interested to
review the information that we post there on a regular basis. The
contents of our website or social media shall not be deemed
incorporated by reference in any filing under the Securities Act of
1933, as amended. Scholar Rock® is a registered trademark of
Scholar Rock, Inc.
Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements regarding Scholar
Rock’s future expectations, plans and prospects, including without
limitation, Scholar Rock’s expectations regarding its growth,
strategy, progress and development timing, the ability of any
individual to affect the growth, strategy, and progress of Scholar
Rock, and the potential of its product candidates and proprietary
platform. The use of words such as “may,” “might,” “could,” “will,”
“should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,”
“project,” “intend,” “future,” “potential,” or “continue,” and
other similar expressions are intended to identify such
forward-looking statements. All such forward-looking statements are
based on management's current expectations of future events and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These risks
and uncertainties include, without limitation, Scholar Rock’s
ability to provide the financial support, resources and expertise
necessary to identify and develop product candidates on the
expected timeline, the data generated from Scholar Rock’s
nonclinical and preclinical studies and clinical trials, and
Scholar Rock’s ability to manage expenses and to obtain additional
funding when needed to support its business activities and
establish and maintain strategic business alliances and new
business initiatives, as well as those risks more fully discussed
in the section entitled "Risk Factors" in Scholar Rock’s Quarterly
Report on Form 10-Q for the year ended September 30, 2023, as well
as discussions of potential risks, uncertainties, and other
important factors in Scholar Rock’s subsequent filings with the
Securities and Exchange Commission. Any forward-looking statements
represent Scholar Rock’s views only as of today and should not be
relied upon as representing its views as of any subsequent date.
All information in this press release is as of the date of the
release, and Scholar Rock undertakes no duty to update this
information unless required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240215040918/en/
Scholar Rock:
Investors & Media Rushmie Nofsinger Scholar Rock
rnofsinger@scholarrock.com ir@scholarrock.com 857-259-5573
Molly MacLeod Scholar Rock mmacleod@scholarrock.com
media@scholarrock.com 802-579-5995
Scholar Rock (NASDAQ:SRRK)
Historical Stock Chart
From Dec 2024 to Jan 2025
Scholar Rock (NASDAQ:SRRK)
Historical Stock Chart
From Jan 2024 to Jan 2025
